Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01, FiscalAI reports.
Whitehawk Therapeutics Price Performance
WHWK opened at $3.08 on Wednesday. Whitehawk Therapeutics has a 12-month low of $1.97 and a 12-month high of $5.49. The firm has a 50 day moving average of $3.63 and a two-hundred day moving average of $3.84.
Institutional Trading of Whitehawk Therapeutics
Several large investors have recently made changes to their positions in the business. OMERS ADMINISTRATION Corp acquired a new stake in shares of Whitehawk Therapeutics in the first quarter worth $40,000. Two Sigma Securities LLC acquired a new position in Whitehawk Therapeutics during the second quarter valued at $46,000. Deutsche Bank AG acquired a new position in Whitehawk Therapeutics during the second quarter valued at $145,000. Bank of America Corp DE purchased a new stake in Whitehawk Therapeutics in the second quarter valued at $159,000. Finally, Seven Fleet Capital Management LP purchased a new stake in Whitehawk Therapeutics in the first quarter valued at $187,000. 52.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Stifel Nicolaus started coverage on Whitehawk Therapeutics in a research report on Wednesday, September 30th. They issued a “buy” rating and a $9.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Wednesday, September 2nd. Finally, Wall Street Zen raised Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $8.33.
Check Out Our Latest Research Report on Whitehawk Therapeutics
Whitehawk Therapeutics Company Profile
Whitehawk Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for the treatment of serious diseases. The company’s activities center on advancing an internal pipeline of therapeutic candidates through preclinical research and clinical development. Whitehawk Therapeutics does not appear to have marketed products at this stage. Its work is focused primarily on research and development, including evaluating potential drug candidates for safety, efficacy and suitability for further clinical testing.
Read More
- Five stocks we like better than Whitehawk Therapeutics
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
- The Trade Desk Beats on Revenue, But the Fine Print Matters
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
